Guerbet

Guerbet: 2023 Strategic Priorities

Retrieved on: 
Monday, January 16, 2023

Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.

Key Points: 
  • Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.
  • In Europe, the European Medicines Agency (EMA) review is expected in the second half of the year.
  • Guerbet also plans to divest the Occlugel technology acquired in 2018, including several ranges of microspheres for use in embolization.
  • Guerbet ultimately aims to enable the development of a major player in artificial intelligence applied to medical imaging in oncology.

Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions

Retrieved on: 
Sunday, January 22, 2023

The financing provided to Intrasense through the Share Capital Increase will allow the Company to strengthen and accelerate the execution of its strategy in the coming years.

Key Points: 
  • The financing provided to Intrasense through the Share Capital Increase will allow the Company to strengthen and accelerate the execution of its strategy in the coming years.
  • This Share Capital Increase will provide Intrasense with a financing horizon of more than 48 months after the completion of the transaction.
  • The breakdown of the Company's share capital and voting rights before and after the Share Capital Increase is presented in Appendix 1 to this press release.
  • Following the completion of the Share Capital Increase, Guerbet plans to file a voluntary tender offer for the balance of the shares of Intrasense at a price of 0.44 euro per share and on the outstanding warrants.

Global Radiation Dose Management Market to Reach $586.7 Million by 2032 - Exclusive DeepTech M-A-P™ Analysis by BIS Research

Retrieved on: 
Friday, December 16, 2022

FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market - A Global and Regional Analysis.

Key Points: 
  • FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market -A Global and Regional Analysis.
  • According to this study, the global radiation dose management market was valued at $212.8 million in 2021 and is projected to reach $586.7 million by 2032.
  • Growing awareness and initiatives for radiation dose management are expected to push the adoption of dose management software.
  • Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

Global Radiation Dose Management Market to Reach $586.7 Million by 2032 - Exclusive DeepTech M-A-P™ Analysis by BIS Research

Retrieved on: 
Friday, December 16, 2022

FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market - A Global and Regional Analysis.

Key Points: 
  • FREMONT, Calif., Dec. 16, 2022 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Radiation Dose Management Market -A Global and Regional Analysis.
  • According to this study, the global radiation dose management market was valued at $212.8 million in 2021 and is projected to reach $586.7 million by 2032.
  • Growing awareness and initiatives for radiation dose management are expected to push the adoption of dose management software.
  • Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects

Retrieved on: 
Thursday, November 3, 2022

Guerbet today announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018.

Key Points: 
  • Guerbet today announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018.
  • This partnership aimed to design, develop and market software solutions to help diagnose and monitor liver and prostate cancers.
  • The termination follows Merative's strategic shift in how it delivers artificial intelligence within its imaging product portfolio.The new Asset Assignment and License Agreement grants Guerbet the ability and autonomy to pursue research and development, and plan for the market launch of Artificial Intelligence solutions.
  • Assets developed during the partnership, including source code for application software, Artificial Intelligence algorithms and the associated intellectual property, are being transferred to Guerbet.

Guerbet: Revenue at September 30, 2022

Retrieved on: 
Thursday, October 20, 2022

Revenue from Diagnostic Imaging increased by 0.5% at CER over the first 9 months, with a Q3 up 4.3% compared with the same period in 2021.

Key Points: 
  • Revenue from Diagnostic Imaging increased by 0.5% at CER over the first 9 months, with a Q3 up 4.3% compared with the same period in 2021.
  • X-Ray revenue at CER decreased by 2.2% at 9 months and 3.1% in Q3 in the wake of the decrease in Optiray sales, while Xenetix sales remained very steady.
  • Against this backdrop, the Group expects 2022 revenue growth to be less than 2% on a like-for-like basis and at constant exchange rates compared with a previously announced range of 2% to 4%.
  • Guerbet (GBT) is listed on Euronext Paris (segment Bmid caps) and generated 732million in revenue in 2021.

Worldwide Angiography Equipment Industry to 2028 - by Device, Procedure, End-users and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, October 17, 2022

The global angiography equipment market is segmented based on the device, procedure, and end-users.

Key Points: 
  • The global angiography equipment market is segmented based on the device, procedure, and end-users.
  • Based on the device, the market is segmented into angiography systems, computed tomography angiography, digital subtraction angiography, magnetic resonance angiography, catheters tube, guide wires, balloons, and others including vascular closure devices and other accessories.
  • Based on the procedure, the market is sub-segmented into coronary angiography, fluorescein angiography, microangiography, neuro-vascular angiography, and peripheral angiography.
  • Geographically the global angiography equipment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.

Fresenius Kabi Expands Contrast Agent Portfolio with Launch of Gadoterate Meglumine Injection, USP

Retrieved on: 
Tuesday, October 4, 2022

Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem.

Key Points: 
  • Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem.
  • View the full release here: https://www.businesswire.com/news/home/20221004005162/en/
    Fresenius Kabi Gadoterate Meglumine Injection, USP is an FDA-approved generic for MRI procedures that is fully substitutable for Dotarem.
  • Fresenius Kabi is pleased to expand our contrast agent portfolio and our support for the radiology community with the launch of Gadoterate Meglumine Injection, USP, said John Ducker, president and CEO of Fresenius Kabi USA.
  • Contrast agents are vital to patient diagnosis, and the addition of Fresenius Kabi Gadoterate Meglumine will provide hospitals and clinics across the U.S. with more high-quality choices to support patient care.

Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)

Retrieved on: 
Wednesday, September 21, 2022

VILLEPINTE, France, Sept. 21, 2022 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging, announced today that the U.S. Food and Drug Administration (FDA) after priority review, approved Elucirem™ (Gadopiclenol), a new macrocyclic GBCA for use in contrast-enhanced magnetic resonance imaging (MRI).

Key Points: 
  • VILLEPINTE, France, Sept. 21, 2022 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging, announced today that the U.S. Food and Drug Administration (FDA) after priority review, approved Elucirem (Gadopiclenol), a new macrocyclic GBCA for use in contrast-enhanced magnetic resonance imaging (MRI).
  • "As a pioneer in MR imaging, thanks to the success of our first gadolinium-based macrocyclic contrast agent, we are delighted with the FDA approval of Elucirem.
  • This approval allows patients and practitioners to benefit from the innovations brought by Elucirem."
  • These factors include those mentioned in the public reports of Guerbet, available on its website www.guerbet.com.

Guerbet: 2022 half-year results

Retrieved on: 
Wednesday, September 21, 2022

The 2022 half-year financial statements, approved by the Board of Directors on Wednesday, September 21, 2022, underwent a limited review by the statutory auditors.

Key Points: 
  • The 2022 half-year financial statements, approved by the Board of Directors on Wednesday, September 21, 2022, underwent a limited review by the statutory auditors.
  • This discipline enabled it to limit the impact of rising costs of raw materials and other supplies (iodine in particular).
  • As of June 30, 2022, equity totaled 429million, compared with 405million on Friday, December 31, 2021.
  • This did not prevent a further improvement in the debt ratio, with a net debt/equity ratio of 0.59 as of June 30, 2022, compared with 0.64 a year earlier.